Claims
- 1. A compound of Formula (I): ##STR18## wherein Z is ##STR19## wherein D, E, F and G may be N, or CR.sub.1 and form pyrimidine ring;
- P is tetrazol-5-yl, CO.sub.2 R.sub.6 or C(O)N(R.sub.6)S(O).sub.q R.sub.10 ;
- R.sub.a is hydrogen or C.sub.1-6 alkyl;
- R.sub.1 is independently hydrogen, Ar, C.sub.1-6 alkyl, or C.sub.1-6 alkoxy;
- R.sub.2 is Ar, C.sub.1-8 alkyl, C(O)R.sub.14 or ##STR20## R.sub.3 and R.sub.5 are independently R.sub.13 OH, C.sub.1-8 alkoxy, S(O).sub.q R.sub.11, N(R.sub.6).sub.2, NO.sub.2, Br, F, I, Cl, CF.sub.3, NHCOR.sub.6 R.sub.13 CO.sub.2 R.sub.7, --X--R.sub.9 --Y, --X(C(R.sub.6).sub.2)OR.sub.6, --(CH.sub.2).sub.m X'R.sub.8 or --X(CH.sub.2).sub.n R.sub.8 wherein each methylene group within --X(CH.sub.2).sub.n R.sub.8 may be unsubstituted or substituted by one or two --(CH.sub.2).sub.n Ar groups;
- R.sub.4 is independently R.sub.11, OH, C.sub.1-5 alkoxy, S(O).sub.q R.sub.11, N(R.sub.6).sub.2, Br, F, I, Cl or NHCOR.sub.6, wherein the C.sub.1-5 alkoxy may be unsubstituted or substituted by OH, methoxy or halogen;
- R.sub.6 is independently hydrogen or C.sub.1-8 alkyl;
- R.sub.7 is independently hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl or C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or more OH, N(R.sub.6).sub.2, CO.sub.2 R.sub.12, halogen or XC.sub.1-10 alkyl; or R.sub.7 is (CH.sub.2).sub.n Ar;
- R.sub.8 is independently R.sub.11, CO.sub.2 R.sub.7, CO.sub.2 C(R.sub.11).sub.2 O(CO)XR.sub.7, PO.sub.3 (R.sub.7).sub.2, SO.sub.2 NR.sub.7 R.sub.11, NR.sub.7 SO.sub.2 R.sub.11, CONR.sub.7 SO.sub.2 R.sub.11, SO.sub.3 R.sub.7, SO.sub.2 R.sub.7, P(O)(OR.sub.7)R.sub.7, CN, CO.sub.2 (CH.sub.2).sub.m C(O)N(R.sub.6).sub.2, C(R.sub.11).sub.2 N(R.sub.7).sub.2, C(O)N(R.sub.6).sub.2, NR.sub.7 C(O)NR.sub.7 SO.sub.2 R.sub.11, OR.sub.6, or tetrazole which is substituted or unsubstituted by C.sub.1-6 alkyl;
- R.sub.9 is independently a bond, C.sub.1-10 alkylene, C.sub.1-10 alkenylene, C.sub.1-10 alkylidene, C.sub.1-10 alkynylene, all of which may be linear or branched, or phenylene, all of which may be unsubstituted or substituted by one of more OH, N(R.sub.6).sub.2, COOH or halogen;
- R.sub.10 is independently C.sub.1-10 alkyl, N(R.sub.6).sub.2 or Ar;
- R.sub.11 is independently hydrogen, Ar, C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or more OH, CH.sub.2 OH, N(R.sub.6).sub.2 or halogen;
- R.sub.12 is independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.2-7 alkynyl;
- R.sub.13 is independently divalent Ar, C.sub.1-10 alkylene, C.sub.1-10 alkylidene, C.sub.2-10 alkenylene, all of which may be unsubstituted or substituted by one or more OH, CH.sub.2 OH, N(R.sub.6).sub.2 or halogen;
- R.sub.14 is independently hydrogen, C.sub.1-10 alkyl, XC.sub.1-10 alkyl, Ar or XAr;
- R.sub.15 is independently C.sub.1-6 alkyl or phenyl substituted by one or two C.sub.1-6 alkyl, OH, C.sub.1-5 alkoxy, S(O).sub.q R.sub.6, N(R.sub.6).sub.2, Br, F, I, Cl, CF.sub.3 or NHCOR.sub.6 ;
- X is independently (CH.sub.2).sub.n, O, NR.sub.6 or S(O).sub.q ;
- X' is independently O, NR.sub.6 or S(O).sub.q ; Y is independently CH.sub.3 or X(CH.sub.2).sub.n Ar;
- Ar is independently: ##STR21## naphthyl, indolyl, pyridyl, thienyl, oxazolidinyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, piperazinyl, pyrrolyl, or pyrimidyl; all of which may be unsubstituted or substituted by one or more Z.sub.1 or Z.sub.2 groups;
- A is independently C.dbd.O, or (C(R.sub.6).sub.2).sub.m ;
- B is independently --CH.sub.2 -- or --O--;
- Z.sub.1 and Z.sub.2 are independently hydrogen, XR.sub.6, C.sub.1-8 alkyl, (CH.sub.2).sub.q CO.sub.2 R.sub.6, C(O)N(R.sub.6).sub.2, CN, (CH.sub.2).sub.n OH, NO.sub.2, F, Cl, Br, I, N(R.sub.6).sub.2, NHC(O)R.sub.6, O(CH.sub.2).sub.m C(O)NR.sub.a SO.sub.2 R.sub.15, (CH.sub.2).sub.m OC(O)NR.sub.a SO.sub.2 R.sub.15, O(CH.sub.2).sub.m NR.sub.a C(O)NR.sub.a SO.sub.2 R.sub.15 or tetrazolyl which may be substituted or unsubstituted by C.sub.1-6 alklyl, CF.sub.3 or C(O)R.sub.6 ;
- m is independently 1 to 3;
- n is independently 0 to 6;
- q is independently 0, 1 or 2;
- provided R.sub.3 and R.sub.5 are not O--O--(CH.sub.2).sub.n Ar or O--OR.sub.6 ;
- or a pharmaceutically acceptable salt thereof.
- 2. A compound of Formula (I) wherein P is CO.sub.2 R.sub.6 ; R.sub.1 is hydrogen, C.sub.1-6 alkyl, or C.sub.1-6 alkoxy; R.sub.2 is Ar, cyclohexyl or C.sub.1-4 alkyl; R.sub.3 and R.sub.5 are independently hydrogen, CO.sub.2 R.sub.6, OH, C.sub.1-8 alkoxy, C.sub.1-8 alkyl, N(R.sub.6).sub.2, NO.sub.2, Br, F, Cl, I, R.sub.13 CO.sub.2 R.sub.7, X(CH.sub.2).sub.n R.sub.8, (CH.sub.2)mX'R.sub.8, or X(C(R.sub.6).sub.2).sub.m OR.sub.6 ; R.sub.4 is hydrogen, OH, C.sub.1-5 alkoxy, N(R.sub.6).sub.2, Br, F, Cl, I, NHCOCH.sub.3, or S(O).sub.q C.sub.1-5 alkyl wherein the C.sub.1-5 alkyl may be unsubstituted or substituted by OH, methoxy or halogen; R.sub.6 is hydrogen, methyl or ethyl; R.sub.7 is hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl or C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or more OH, N(R.sub.6).sub.2, CO.sub.2 R.sub.12, halogen, or R.sub.7 is (CH.sub.2).sub.n Ar wherein n is zero or 1 and Ar is substituted phenyl; R.sub.11 is hydrogen, phenyl, pyridyl all of which may be substituted or unsubstituted by one or two C.sub.1-4 alkyl groups; C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, all of which may be substituted or unsubstituted by one or more OH, CH.sub.2 OH, N(R.sub.6).sub.2, or halogen; R.sub.12 is hydrogen or C.sub.1-6 alkyl; R.sub.13 is phenyl, pyridyl, or C.sub.2-10 alkylene, all of which may be unsubstituted or substituted by one or more CO.sub.2 R.sub.6, OH, CH.sub.2 OH, N(R.sub.6).sub.2, or halogen; R.sub.15 is hydrogen or C.sub.1-6 alkyl.
- 3. A compound of claim 2 wherein P is CO.sub.2 H; R.sub.1 is hydrogen, C.sub.1-6 alkyl, or C.sub.1-6 alkoxy; R.sub.2 is a group Ar wherein Ar is a group (a) or (b) and in said group (a) or (b), Z.sub.1 and Z.sub.2 are independently hydrogen, CO.sub.2 R.sub.6, (CH.sub.2).sub.n OH, C.sub.1-4 alkyl or C.sub.1-6 alkoxy and A is CH.sub.2, and one or both Bs are O; R.sub.3 is Br, Cl, C.sub.1-8 alkoxy or X(CH.sub.2).sub.n R.sub.8, wherein X is O, n is 0, 1, or 2, and R.sub.8 is selected from: CO.sub.2 H, OH, tetrazolyl optionally substituted by C.sub.1-8 alkyl; CONR.sub.7 SO.sub.2 R.sub.11 wherein R.sub.7 is H or C.sub.1-8 alkyl, R.sub.11 is C.sub.1-8 alkyl or phenyl optionally substituted by Br, Cl, F, C.sub.1-8 alkyl; or R.sub.8 is phenyl or pyridyl substituted by one or more Br, Cl, CO.sub.2 H, CH.sub.2 OH; R.sub.5 is methoxy or N(R.sub.6).sub.2 wherein R.sub.6 is H or methyl; R.sub.4 is hydrogen; R.sub.6 is hydrogen, methyl or ethyl; R.sub.7 is hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl or C.sub.2-8 alkynyl, all of which may be unsubstituted or substituted by one or more OH, N(R.sub.6).sub.2, CO.sub.2 R.sub.12, halogen, or R.sub.7 is (CH.sub.2).sub.n Ar wherein R.sub.7 is (CH.sub.2).sub.n Ar and n is zero or 1 and Ar is phenyl substituted or unsubstituted by halogen or C.sub.1-5 alkoxy; R.sub.11 is hydrogen, phenyl, pyridyl wherein the phenyl or pyridyl be substituted or unsubstituted by one or two C.sub.1-4 alkyl groups; C.sub.1-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl, all of which may be substituted or unsubstituted by one or more OH, CH.sub.2 OH, N(R.sub.6).sub.2, or halogen; R.sub.12 is hydrogen or C.sub.1-6 alkyl; R.sub.13 is phenyl, pyridyl, or C.sub.2-10 alkylene, all of which may be unsubstituted or substituted by one or more CO.sub.2 R.sub.6, OH, CH.sub.2 OH, N(R.sub.6).sub.2, or halogen; R.sub.15 is hydrogen, ethyl, isopropyl, n-butyl, cyclopropylmethyl or cyclopropylethyl.
- 4. A compound of claim 1 selected from:
- E-3-{5-�(2-carboxyphenyl)methoxy-4-methoxy!phenyl-6-n-propoxypyrimid-4yl!-2-{2-methoxy-4, methylenedioxybenzyl!-prop-2-enoic acid, and
- E-3-�6-n-Propoxy-5-�2-(2-carboxyphenyl)methoxy-4-methoxy!phenylpyrimid-4-yl!-2-�2-methoxy-4,5-methylenedioxybenzyl!-2-propenoic acid potassium salt.
- 5. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
- 6. A compound of claim 1 for use as an endothelin receptor antagonist.
- 7. A method of treatment of diseases caused by an excess of endothelin comprising administering to a subject in need thereof, an effective amount of an endothelin receptor antagonist of claim 1.
- 8. A method of treating renal failure or cerebrovascular disease which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 9. A method for the prophylaxis and treatment of radiocontrast induced renal failure which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 10. A method of treatment of congestive heart failure which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 11. A method of treatment of unstable angina, coronary vasospasm and myocardial salvage which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 12. A method of preventing or treating restenosis which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 13. A method of treatment of pulmonary hypertension which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 14. A method of treatment of stroke or subarachnoid hemorrhage which comprises administering to a subject in need thereof, an effective amount of a compound of claim 1.
- 15. A process for preparing a compound of Formula (I) by:
- (a) reaction of a compound of formula (II): ##STR22## wherein R.sub.3a, R.sub.4a and R.sub.5a represent the groups R.sub.3, R.sub.4 and R.sub.5 as defined for Formula (I) hereinabove, or a protected form or precursor thereof and R.sub.1a represents a group R.sub.1 as defined for Formula (I) hereinabove, or a protected form or precursor thereof);
- with a compound of Formula (III): ##STR23## wherein R.sub.2 and P are as defined for formula (I) hereinabove and n is 0 to 5; followed if necessary or desired by:
- (b) functional group interconversion of a compound of formula (I) into a different compound of formula (I) e.g.
- (i) when formula (I) contains an ester group e.g. CO.sub.2 R.sub.6, conversion to a corresponding compound wherein R.sub.6 represents hydrogen;
- (ii) when formula (I) contains a hydroxy group (e.g. in R.sub.3, R.sub.4 or R.sub.5) conversion to a different group, eg a group O(CH.sub.2)Ar where Ar is as previously defined, by methods well known in the art; and/or
- (c) salt formation.
FIELD OF INVENTION
This is a 371 of PCT/US96/12582 filed on Aug. 2, 1996. This application claims benefit of Provisional Appl. Ser. No. 60/001,791 filed Aug. 2, 1995 and Provisional Appl. Ser. No. 60/011,148 filed Feb. 1, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/US96/12582 |
8/2/1996 |
|
|
9/27/1996 |
9/27/1996 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/04781 |
2/13/1997 |
|
|
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4886816 |
Franckowiak et al. |
Dec 1989 |
|
4952592 |
Torija et al. |
Aug 1990 |
|
5420133 |
Dhanoa et al. |
May 1995 |
|